# SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy

> **NCT04931979** · PHASE2 · UNKNOWN · sponsor: **Prof. Dr. med. Christian Gratzke** · enrollment: 49 (estimated)

## Conditions studied

- Urologic Cancer
- Biochemical Recurrence of Malignant Neoplasm of Prostate

## Interventions

- **DRUG:** Pembrolizumab Injection [Keytruda]
- **RADIATION:** Salvage Radiation Therapy (SRT)

## Key facts

- **NCT ID:** NCT04931979
- **Lead sponsor:** Prof. Dr. med. Christian Gratzke
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-20
- **Primary completion:** 2025-07-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2023-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04931979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04931979, "SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04931979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*